Related Experiment Video
Updated: Apr 28, 2026
05:29
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
3.2K
Arsenic Trioxide and the MNK1 Inhibitor AUM001 Exert Synergistic Anti-Glioblastoma Effects by Modulating Key
Yue Hao1, Charles Shaffer1,2, Nanyun Tang1
1Clinical Genomics and Therapeutics Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA.
Brain Sciences
|February 27, 2026
Summary
Combining arsenic trioxide (ATO) with AUM001 effectively targets glioblastoma stem cells (GSCs), especially in resistant models. This combination therapy shows promise for overcoming treatment resistance and improving outcomes in glioblastoma (GBM).
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Glioblastoma (GBM) exhibits significant heterogeneity, leading to limited efficacy of conventional treatments like arsenic trioxide (ATO).
- Treatment resistance in GBM necessitates the development of novel combination strategies.
- Glioblastoma stem cells (GSCs) are key drivers of tumor recurrence and treatment failure.
Purpose of the Study:
- To evaluate the therapeutic effects of arsenic trioxide (ATO) alone and in combination with the MNK1 inhibitor AUM001 in glioblastoma.
- To investigate the molecular determinants of sensitivity and synergy in patient-derived xenograft (PDX) models.
- To assess the combination's impact on glioblastoma stem cell (GSC) populations.
Main Methods:
- Therapeutic efficacy assessment of ATO and AUM001 combination in patient-derived glioblastoma xenograft models.
- Investigation of molecular mechanisms underlying sensitivity and synergistic effects.
- Transcriptomic analysis to identify molecular signatures associated with treatment response.
Main Results:
- The combination of ATO and AUM001 demonstrated synergistic cytotoxicity, particularly in ATO-resistant glioblastoma models, including the mesenchymal subtype.
- The combination significantly reduced glioblastoma stem cell (GSC) frequency compared to single-agent treatments.
- Synergistic responses were linked to molecular signatures involving cellular organization, amino acid transport, ion channels, and extracellular matrix components.
Conclusions:
- Targeting the MNK1 pathway with AUM001 in combination with ATO is a promising strategy to eradicate GSCs and overcome GBM treatment resistance.
- Specific molecular pathways, including translation, cell cycle, and ion transport, modulate the synergistic efficacy of the ATO-AUM001 combination.
- These findings suggest potential biomarkers for patient stratification in future clinical trials involving ATO-based glioblastoma treatments.
Related Concept Videos
02:38Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
02:23Abnormal Proliferation
4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
01:19Interactions Between Signaling Pathways
4.7K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
01:22PI3K/mTOR/AKT Signaling Pathway
5.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.1K